Adult Dosing

Management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis, uric acid lithiasis with or without calcium stones

Severe Hypocitraturia (Urinary Citrate <150 mg/day)

• Initial: 60 mEq/day, i.e. 30 mEq bid or 20mEq tid with meals or within 30 minutes after meals or bedtime snack
• Max: 100 mEq per day

Mild to Moderate Hypocitraturia (Urinary Citrate >150 mg/day)

• Initial: 30 mEq per day, i.e. 15 mEq bid or 10 mEq tid with meals or within 30 minutes after meals or bedtime snack
• Max: 100 mEq per day

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Management of renal tubular acidosis with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis
• Uric acid lithiasis with or without calcium stones

• Hypersensitivity to any of the ingredients of the product
• Renal impairment
• Hyperkalemia
• Active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones)
• Conditions predisposing to hyperkalemia (chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown, or the administration of a potassium-sparing agent like triamterene, spironolactone or amiloride)
• Patients in whom there is cause for arrest or delay in tablet passage from the GI tract like delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking an anticholinergic medication
• Peptic ulcer disease
• Renal insufficiency (glomerular filtration rate <0.7 ml/kg/min)

• N/A

Renal Dose Adjustment

• Renal impairment: Contraindicated

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Potassium citrate may produce hyperkalemia and cardiac arrest in patients with impaired mechanisms for excreting potassium
• Use of potassium citrate should be avoided in chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure
• Carefully monitor for signs of hyperkalemia with regular blood tests and ECGs
• Upper gastrointestinal mucosal lesions have been reported with use of potassium citrate. If severe vomiting, abdominal pain or gastrointestinal bleeding is observed, discontinue treatment promptly and investigate the possibility of bowel perforation or obstruction

Cautions: Use cautiously in

• Recent myocardial infarction
• Congestive heart failure

Pregnancy Category:C

Breastfeeding: Safety unknown. As per manufacturer, nursing mothers should receive the drug only of clearly required.

• GI: Abdominal discomfort, vomiting, diarrhea, loose bowel movements, nausea, GI bleeding, GI lesions, intact tablet matrices in stool
• MISC: Hyperkalemia, Cardiac arrest

• Urinary tract alkalinizer; absorbed citrate induces an alkaline load which in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate
• Metabolism: Unknown
• Excreted in urine
• Half-life: Unknown

US Trade Name(s)

• Urocit-K

US Availability

potassium citrate (generic)

• Extended Release TABS: 5, 10 mEq

Urocit-K

• ETABS: 5, 10, 15 mEq

Canadian Trade Name(s)

• Urocit-K

Canadian Availability

Urocit-K

• Extended Release TABS: 540, 1080 mg

UK Trade Name(s)

• Cymaclear

UK Availability

potassium citrate (generic)

• SOLN: 1.5 g/5 mL

Cymaclear

• SOLN: 1.5 g/5 mL

Australian Trade Name(s)

• Urocit-K

Australian Availability

Urocit-K

• Extended Release TABS: 10 mEq

[Outline]

Neurologic

Neurotoxins

Pricing data from www.DrugStore.com in U.S.A.

• Potassium Citrate 10 MEQ (1080 MG) TBCR [Bottle] (UPSHER-SMITH)
  100 (1080 mg) = $100.98
  200 (1080 mg) = $201.97
• Potassium Citrate 5 MEQ (540 MG) TBCR [Bottle] (UPSHER-SMITH)
  100 (540 mg) = $75.59
  200 (540 mg) = $140.39

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• POTASSIUM CITRATE 1080 mg (Physicians Total Care, Inc.)
• Potassium citrate 10 MEQ Extended Release Tablet (Rising Pharmaceuticals Inc)
• Potassium citrate 10 MEQ Extended Release Tablet (UPSHER-SMITH LABORATORIES, INC.)
• Potassium citrate 5 MEQ Extended Release Tablet (Rising Pharmaceuticals Inc)
• Potassium citrate 5 MEQ Extended Release Tablet (UPSHER-SMITH LABORATORIES, INC.)